Gilead Sciences (GILD) vs Moderna (MRNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Moderna (MRNA) has outperformed Gilead Sciences (GILD) over the past year, gaining 618.7% versus a gain of 25.7%. Over five years, GILD leads with a +117.1% price change compared with -39.4% for MRNA. Gilead Sciences is the larger company by market cap ($181.04 billion vs $77.64 billion), about 2.3 times the size.
Gilead Sciences pays a dividend yielding 2.21%, while Moderna does not currently pay one. Gilead Sciences converts more of its revenue into profit, with a net margin of 28.9% versus -145.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GILD | MRNA |
|---|---|---|
| Share price | $146.00 | $194.47 |
| Market cap | $181.04B | $77.64B |
| 1-day change | -0.58% | -1.02% |
| YTD return | +19.64% | +566.26% |
| 1-year return | +25.75% | +618.65% |
| 5-year return | +117.14% | -39.40% |
| Forward P/E | 14.76 | — |
| EPS (TTM) | $-2.65 | $-7.98 |
| Dividend yield | 2.21% | 0.00% |
| Annual dividend | $3.22 | $0.00 |
| Revenue (latest FY) | $29.44B | $1.94B |
| Revenue growth (YoY) | +2.40% | -39.93% |
| Net income (latest FY) | $8.51B | $-2.82B |
| Gross margin | 78.83% | 55.35% |
| Operating margin | 34.04% | -158.13% |
| Net margin | 28.90% | -145.16% |
| 52-week high | $157.29 | $212.22 |
| 52-week low | $114.02 | $22.28 |
| Distance from 52-week high | -7.18% | -8.36% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +9.09% | -37.78% |
| Average volume | 6.01M | 17.44M |
| Shares outstanding | 1.24B | 399.24M |
| Employees | 17,000 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Gilead Sciences is about 2.3 times larger than Moderna by market value ($181.04B vs $77.64B).
- MRNA has outperformed GILD by 592.9 percentage points over the past year.
- Gilead Sciences offers a meaningfully higher dividend yield (2.21% vs 0.00%).
- Gilead Sciences is more profitable, keeping 28.9 cents of every revenue dollar as net income versus -145.2 cents for Moderna.
- Gilead Sciences grew revenue faster in its latest fiscal year (+2.40% vs -39.93%).
About Gilead Sciences
GILD stock →Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17,000 employees
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
GILD vs MRNA FAQ
Which is bigger, Gilead Sciences or Moderna?
Gilead Sciences (GILD) is larger, with a market capitalization of $181.04B compared with $77.64B for Moderna (MRNA).
Which stock has performed better over the past year, GILD or MRNA?
MRNA returned +618.65% over the past 12 months, compared with +25.75% for GILD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Gilead Sciences or Moderna?
Gilead Sciences pays a dividend yielding 2.21%, while Moderna does not currently pay a regular dividend.
Are Gilead Sciences and Moderna in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.